Meningioma harboring IDH1 R132H mutation: a case report

Meningiomas are the most common primary central nervous system tumors. Monosomy of chromosome 22 is the most frequently reported genetic abnormality in meningioma and the occurrence of IDH1 mutations in meningioma is exceedingly rare. We report an uncommon case of IDH1 R132H-mutant meningioma. A 69-year-old man presented with two intracranial masses, one of which was identified as an IDH1 R132H-mutant meningioma by next-generation sequencing and further confirmed by pyrosequencing and immunohistochemistry. The rarity of this molecular finding and the potentially favorable prognosis observed in previously reported cases highlight the need for its recognition as a distinct molecular subset. Isocitrate dehydrogenase-targeted therapy may represent a future therapeutic option, pending validation through prospective studies and larger case series.

Authors

Institutions

Publication Details

Journal
Journal of Pathology and Translational Medicine
Published
2026-11-03
DOI
https://doi.org/10.4132/jptm.2026.08.19
Primary Topic
Meningioma and schwannoma management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Meningioma harboring IDH1 R132H mutation: a case report

Chung Lee, Jong Pil Park, Se Hoon Kim, Soyeon Ahn
Journal of Pathology and Translational Medicine
Meningioma and schwannoma management
article

Meningioma harboring IDH1 R132H mutation: a case report

Chung Lee, Jong Pil Park, Se Hoon Kim, Soyeon Ahn
article en

Abstract

Meningiomas are the most common primary central nervous system tumors. Monosomy of chromosome 22 is the most frequently reported genetic abnormality in meningioma and the occurrence of IDH1 mutations in meningioma is exceedingly rare. We report an uncommon case of IDH1 R132H-mutant meningioma. A 69-year-old man presented with two intracranial masses, one of which was identified as an IDH1 R132H-mutant meningioma by next-generation sequencing and further confirmed by pyrosequencing and immunohistochemistry. The rarity of this molecular finding and the potentially favorable prognosis observed in previously reported cases highlight the need for its recognition as a distinct molecular subset. Isocitrate dehydrogenase-targeted therapy may represent a future therapeutic option, pending validation through prospective studies and larger case series.

Journal of Pathology and Translational Medicine
Yonsei University (KR), Yonsei University Health System (KR)
Openalex Percentile: Top 13%
Meningioma and schwannoma management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon